Observational studyBMJ open respiratory research2026
Development and validation of LPCPIS: an integrated clinical, biomarker and lung ultrasound score for the diagnosis of ventilator-associated pneumonia.
Observational study in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate whether the performance of the modified Clinical Pulmonary Infection Score (CPIS) for diagnosis of ventilator-associated pneumonia (VAP) could be improved by incorporating procalcitonin (PCT), lactate and a standardised lung ultrasound score (LUS).
designProspective observational study.
settingInternal medicine and respiratory intensive care units (ICUs) of a tertiary care centre in India over 18 months.
participants97 adult patients receiving invasive mechanical ventilation for 48 hours or more with suspected VAP. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was the diagnostic accuracy (area under the receiver operating characteristic curve (AUC)) of the integrated score compared with a reference standard of quantitative bronchoalveolar lavage culture (>10
resultsOf the 97 patients, 70 (72.2%) were culture positive. The modified CPIS alone demonstrated limited diagnostic utility (AUC 0.686). In contrast, the novel 4-point Lactate-Lung Ultrasound-Procalcitonin-Clinical Pulmonary Infection Score (LPCPIS) score (integrating CPIS >5, lactate >2.15 mmol/L, PCT >1.3 ng/mL and LUS >14) achieved excellent discriminatory ability (AUC 0.919, 95% CI 0.844 to 0.976). At a cut-off of ≥2, the score yielded 95.7% sensitivity and 77.8% specificity. Crucially, a 4-point LPCPIS bedside score of ≤1 was associated with a highly diminished probability of VAP, yielding a negative predictive value of 100% in this cohort. In comparison, a score ≥3 strongly indicated a high likelihood of VAP, with a positive predictive value of 96.5% and specificity of 92.6%, pending definitive microbiological confirmation.
conclusionsThe novel 4-point LPCPIS bedside score demonstrates significant diagnostic superiority over the traditional modified CPIS (AUC 0.919 vs 0.686). By integrating bedside lung ultrasound with biomarkers, this simplified pragmatic tool provides impressive discriminatory power, allowing clinicians in resource-limited settings to reliably assess probability of VAP and guide early antimicrobial decision-making while awaiting definitive microbiological cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.